Application of baicalein in preparation of medicine for preventing or treating metabolic dysfunction related steatohepatitis

By using scutellaria scutellaria to treat metabolic dysfunction-related steatohepatitis, the problem of lack of effective drugs in the prior art has been solved. scutellaria scutellaria significantly improves the clinical symptoms of MASH and has broad market prospects.

CN118976021AInactive Publication Date: 2024-11-19FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411213143.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art lacks effective drugs to treat metabolic dysfunction-related steatohepatitis (MASH), and traditional treatments have toxicity and side effects, and new anti-MASH drugs are urgently needed.

Method used

Scutellaria baicalensis can improve the symptoms of steatohepatitis, such as reducing serum enzyme levels, reducing steatosis and inflammation, and improving liver fibrosis. .

Benefits of technology

Scutellaria baicalensis significantly reduces the number of lipid droplets, improves liver steatosis and inflammation, and reduces serum ALT, AST, TC, and TG content. It has potentially broad market prospects as a new anti-MASH therapeutic drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976021A_ABST
    Figure CN118976021A_ABST
Patent Text Reader

Abstract

The invention discloses application of baicalein in preparation of a medicine for preventing or treating metabolic dysfunction related steatohepatitis, and belongs to the technical field of biological medicine. For the metabolic dysfunction related steatohepatitis, the baicalein has the effects of improving weight gain or weight loss caused by the metabolic dysfunction related steatohepatitis induced by different modes, reducing the levels of ALT and AST in serum, reducing the content of TC and TG, and improving the metabolic dysfunction related steatohepatitis. The effects of improving liver fatty degeneration, lipid accumulation, inflammation in liver lobules, liver fibrosis and lipid deposition of human normal liver cells and human liver cancer cells are achieved. Therefore, the baicalein is expected to be developed into a novel anti-MASH therapeutic drug, and has a wide market prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of baicalin in the preparation of a medicine for preventing or treating fatty hepatitis associated with metabolic dysfunction. Background Art

[0002] Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) is a further development of metabolic dysfunction-associated fatty liver disease (MASLD). MASH patients are often accompanied by steatosis, inflammation, and liver fibrosis, and can further develop into cirrhosis. If not treated in time, the risk of cirrhosis will increase, inducing liver failure and liver cancer in patients, and ultimately leading to death. Therefore, screening new active compounds with low toxicity and few side effects for their clinical treatment of MASH remains a major problem that needs to be solved urgently in the medical community.

[0003] Natural small molecule drugs derived from traditional Chinese medicine have always been an important source for the discovery of new drug lead compounds due to their rich chemical structures and diverse pharmacological activities. Discovering new anti-MASH lead compounds from traditional Chinese medicine is currently a research hotspot.

[0004] Baicalin (also known as SkullcapflavoneⅡ, SkullcapflavoneⅡ, SFⅡ) is a relatively new active compound extracted from the medicinal plant Scutellaria baicalensis. Existing studies have shown that baicalin has anti-inflammatory, antioxidant, and anti-cancer pharmacological effects. The CAS number of baicalin is 55084-08-7, the molecular weight is 374.34, and the structural formula is:

[0005]

[0006] So far, there is no report on the use of baicalin in the treatment of MASH. Summary of the invention

[0007] In order to overcome the above-mentioned shortcomings of the prior art, the object of the present invention is to provide the use of baicalin in the preparation of a drug for preventing or treating fatty hepatitis associated with metabolic dysfunction.

[0008] In order to achieve the above object, the present invention adopts the following technical solutions:

[0009] The first aspect of the present invention discloses the use of baicalin in the preparation of a drug for preventing or treating fatty hepatitis associated with metabolic dysfunction.

[0010] Preferably, the drug is a drug that can improve weight gain or weight loss caused by metabolic dysfunction-related fatty hepatitis.

[0011] Preferably, the drug is a drug capable of reducing the level of ALT in serum.

[0012] Preferably, the drug is a drug that can reduce the level of AST in serum.

[0013] Preferably, the drug is a drug that can reduce the TC content in serum.

[0014] Preferably, the drug is a drug that can reduce the TG content in serum.

[0015] Preferably, the drug is a drug that can improve hepatic steatosis.

[0016] Preferably, the drug is a drug that can improve ballooning of hepatocytes.

[0017] Preferably, the drug is a drug that can improve lipid accumulation.

[0018] Preferably, the drug is a drug that can improve inflammation in liver lobules.

[0019] Preferably, the drug is a drug that can improve liver fibrosis.

[0020] Preferably, the drug is a drug capable of improving lipid deposition in normal human hepatocytes.

[0021] Preferably, the drug is a drug that can improve lipid deposition in human liver cancer cells.

[0022] Preferably, the dosage of baicalein is 5 to 15 mg / kg.

[0023] Preferably, the drug is in the form of tablets, capsules, granules, oral liquids, premixes, pills or sustained-release preparations for oral administration, either alone or mixed with pharmaceutically acceptable excipients or diluents, or in the form of ointments or injections for non-oral administration.

[0024] Preferably, baicalein is the only active ingredient.

[0025] The second aspect of the present invention discloses a drug for preventing or treating metabolic dysfunction-related fatty hepatitis, comprising baicalin and one or more pharmaceutically acceptable carriers and / or excipients, or comprising baicalin and other drugs for treating metabolic dysfunction-related fatty hepatitis.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] The application of baicalin provided by the present invention in the preparation of a drug for preventing or treating metabolic dysfunction-related fatty hepatitis is to simulate the different clinical pathogenesis of MASH by constructing two animal models of MASH in vivo (methionine choline deficiency (MCD) model and high fat and high cholesterol (HFHC) model) to evaluate the beneficial effects of baicalin in treating MASH. The results of liver histopathology showed that compared with the model group, baicalin could significantly reduce the number of lipid droplet vacuoles and ballooning, improve hepatic fatty degeneration, inflammation and fibrosis in the liver lobules; reduce the levels of ALT and AST and the content of TC and TG in serum. The efficacy of baicalin was evaluated in vitro using normal human liver cells (L02) and human liver cancer cells (HepG2) induced by sodium oleate (OA) + sodium palmitate (PA), and the results showed that baicalin could significantly reduce the lipid deposition and inflammatory response induced by OA + PA. Therefore, baicalin is expected to be developed as a new anti-MASH therapeutic drug with broad market prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The diagram shows the improvement effect of baicalin on MASH mice induced by MCD diet, wherein A: experimental flow chart; B: final body weight; C: liver weight; D: serum ALT level; E: serum AST level; F: serum TC level; G: serum TG content; H: liver photos, liver ultrasound results, H&E staining, Oil Red O staining; I: Masson staining; J: Sirius red (PSR) staining; K: liver-kidney ratio; L: Oil Red O staining result statistics; M: Masson staining result statistics; N: PSR staining result statistics; n=6, ## P<0.01vs.MCS. * P<0.05, ** P<0.01vs.MCD.Scale bar:20μm;

[0029] Figure 2 The diagram shows the improvement effect of baicalin on HFHC diet-induced MASH mice, wherein A: experimental flow chart; B: final body weight; C: liver weight; D: serum ALT level; E: serum AST level; F: serum TC level; G: serum TG content; H: liver photos, liver ultrasound results, H&E staining, Oil Red O staining; I: Masson staining; J: PSR staining; K: liver-kidney ratio; L: Oil Red O staining result statistics; M: Masson staining result statistics; N: PSR staining result statistics; n=6, ## P<0.01vs.Control. * P<0.05, ** P<0.01vs.HFHC.Scale bar:20μm;

[0030] Figure 3 The diagram shows the improvement effect of baicalin on OA+PA-induced L02 and HepG2, wherein A: Oil Red O staining and Bodipy fluorescence staining of L02; B: Oil Red O staining statistics of L02; C: Bodipy fluorescence staining statistics of L02; D: Oil Red O staining and Bodipy fluorescence staining of HepG2; E: Oil Red O staining statistics of HepG2; F: Bodipy fluorescence staining statistics of HepG2; ## P<0.01vs.Control. * P<0.05, ** P<0.01 vs.FFA.Scale bar:20μm. DETAILED DESCRIPTION

[0031] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.

[0032] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.

[0033] Herein, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are for simplicity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values ​​within the range (including integers and fractions).

[0034] In this document, unless otherwise specified, “includes,” “including,” “contains,” “has,” or similar terms cover the meanings of “consisting of” and “mainly consisting of,” for example, “A includes a” covers the meanings of “A includes a and other” and “A only includes a.”

[0035] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.

[0036] Herein, unless otherwise specified, the term "dosage form" is also referred to as "preparation form", "medicament", "pharmaceutical preparation", etc. According to the present invention, pharmaceutical dosage forms include but are not limited to solid or liquid forms for oral administration or rectal administration, or for injection, or for non-oral administration, for use alone or in combination with a non-toxic pharmaceutically acceptable carrier. Solid dosage forms for oral administration include but are not limited to capsules, tablets, pills, premixes, sustained-release preparations, powders and granules. In such solid dosage forms, the active compound may be mixed with at least one inert pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or the following: a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic; c) humectants such as glycerol; d) disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarder such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glyceryl monostearate; h) adsorbents such as kaolin and bentonite; i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also contain a buffer. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. Liquid dosage forms may also contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuran alcohol, polyethylene glycol and fatty acid esters of sorbitan and mixtures thereof, in addition to the active compound. According to the present invention, the route of administration of baicalein includes but is not limited to intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.

[0037] Herein, unless otherwise specified, the term "pharmaceutical composition" may be used interchangeably with "composition", which comprises the active ingredient baicalein and any one or more other drugs capable of treating metabolic dysfunction-related fatty hepatitis, which synergize with baicalein to treat metabolic dysfunction-related fatty hepatitis.

[0038] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0039] The following examples use conventional instruments and equipment in the art. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The various raw materials used in the following examples, unless otherwise specified, are conventional commercial products, and their specifications are conventional specifications in the art.

[0040] Scutellariae new medicine (SFⅡ) was purchased from Baoji Chenguang Biotechnology Co., Ltd., with the catalog number HS21302B1; the positive drug (Resmetirom, Res) was purchased from TargetMol Chemicals Inc., with the catalog number 158082.

[0041] 1. Establishment of animal model (in vivo) and efficacy evaluation

[0042] One hundred SPF C57BL / 6 male mice, 8-9 weeks old, weighing 22-25 g, were housed in the animal room of the Pharmacy Department of the First Affiliated Hospital of Air Force Medical University, with a barrier environment at room temperature of (22±1)°C, relative humidity of 30%-60%, 12 h light / 12 h dark, and free access to food and water.

[0043] Example 1: MCD diet-induced MASH model to evaluate the efficacy of baicalin

[0044] Model building: Figure 1As shown in A, mice were fed with MCD diet for 4 weeks to induce MASH. After the model was successfully established, the modeled mice were randomly divided into a model group (MCD, free drinking water), a low-dose baicalin group (SFⅡ, intragastric administration, 5 mg / kg / day), a high-dose baicalin group (SFⅡ, intragastric administration, 15 mg / kg / day) and a positive drug group (Res, intragastric administration, 15 mg / kg / day), and mice without modeling were used as a control group (MCS, free drinking water). Among them, the mice in the MCS group and the MCD group had free drinking water for 4 weeks, and the mice in each drug group were intragastricly administered with the above drugs for 4 weeks. At the end of the experiment, the mice were fasted for 1 day, blood was collected from the orbital venous plexus, and serum was separated (3500rpm, 20min, 4℃) and stored in a -80℃ refrigerator. Then, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG) and cholesterol (TC) in the serum of the mice were determined according to the instructions of the kit. The mice were anesthetized and killed, and the livers were quickly removed and cleaned with saline to remove residual blood. The right lobe of the liver was fixed in 4% paraformaldehyde solution and embedded in OTC for liver tissue pathology detection (H&E staining, Oil Red O staining, Masson staining, and Sirius Red (PSR) staining). The remaining liver tissue was placed in a cryovial and quickly frozen with liquid nitrogen and stored in a -80°C refrigerator for later use.

[0045] Efficacy evaluation: (1) Important test indicators: body weight, liver weight; (2) Biochemical indicators: ALT, AST, TG and TC levels; (3) Liver pathology: H&E staining, Oil Red O staining, NASH score (hepatic steatosis, intralobular inflammation, hepatocyte ballooning and comprehensive score); (4) Inflammation and fibrosis detection: Masson staining, PSR staining.

[0046] Table 1 Comparison of baicalin on MASH score of liver tissue in mice with non-alcoholic steatohepatitis induced by MCD diet (n=6, )

[0047]

[0048] ## P<0.01vs.MCS.*P<0.05,**P<0.01vs.MCD.

[0049] Test results: Figure 1 As shown in Figures B-J and Table 1, baicalin can significantly balance the body weight of mice induced by MCD diet ( Figure 1 B) and liver weight ( Figure 1 C); reduce serum ALT and AST levels ( Figure 1 D and E), reduce serum TC and TG levels ( Figure 1F and G), significantly improved hepatic steatosis, lipid accumulation, intralobular inflammation and fibrosis ( Figure 1 As shown in Table 1, baicalin can improve MASH in mice induced by MCD diet.

[0050] Example 2: Evaluation of the efficacy of baicalin in the MASH model induced by HFHC diet

[0051] Model building: Figure 2 As shown in A, mice were fed HFHC diet for 8 weeks to induce MASH. After the model was successful, the modeled mice were randomly divided into a model group (HFHC, free drinking water), a low-dose baicalin group (SFⅡ, intragastric administration, 5 mg / kg / day), a high-dose baicalin group (SFⅡ, intragastric administration, 15 mg / kg / day) and a positive drug group (Res, intragastric administration, 15 mg / kg / day), and mice without modeling were used as a control group (Control, free drinking water). Among them, the mice in the Control group and the HFHC group had free drinking water for 8 weeks, and the mice in each drug group were given the above drugs by intragastric administration for 8 weeks. At the end of the experiment, the mice were fasted for 1 day, but not water, and blood was collected from the orbital venous plexus. The serum was separated (3500rpm, 20min, 4℃) and stored in a -80℃ refrigerator. The mice were anesthetized and killed, and the livers were quickly removed and cleaned with saline to remove residual blood. The right lobe of the liver of all mice was fixed in 4% paraformaldehyde solution and embedded in OTC for liver tissue pathology detection. The remaining liver tissue was placed in a cryovial and quickly frozen with liquid nitrogen and stored in a -80°C refrigerator for later use.

[0052] Efficacy evaluation: (1) Important test indicators: body weight, liver weight; (2) Biochemical indicators: ALT, AST, TG and TC content; (3) Liver pathology: H&E staining, Oil Red O staining, NASH score (hepatic steatosis, intralobular inflammation, hepatocyte ballooning, comprehensive score); (4) Inflammation and fibrosis detection: Masson staining, PSR staining.

[0053] Test results: Figure 2 As shown in B-J, baicalin can reduce the body weight of mice induced by HFHC diet ( Figure 1 B) and liver weight ( Figure 1 C); reduce serum ALT and AST levels ( Figure 1 D and E), reduce serum TC and TG levels ( Figure 1 F and G), significantly improved hepatic steatosis, lipid accumulation, intralobular inflammation and fibrosis ( Figure 1 H~N). Baicalin can improve MASH in mice induced by HFHC diet.

[0054] 2. Establishment of cell model (in vitro) and efficacy evaluation

[0055] Example 3: Sodium oleate (OA) + sodium palmitate (PA) induced fatty degeneration model of normal human liver cells (L02) and human liver cancer cells (HepG2) to evaluate the efficacy of baicalin

[0056] Model establishment: L02 and HepG2 were cultured in DMEM medium containing 10% fetal bovine serum and 1% double antibody (penicillin-streptomycin mixture) at 37°C and 5% CO2. When the cell confluence reached about 95%, 2×10 cells were added to each well. 5 cell / mL were plated in 6-well plates and randomly divided into 5 groups: blank control group, model group, model + baicalin low and high dose groups and model + positive drug group. After the cells adhered to the wall, the blank control group was given normal culture medium containing DMSO, the model group was given a culture medium mixture containing DMSO and 500μM OA+250μMPA, the model + baicalin low and high dose groups were given a culture medium mixture of 10μM and 20μM baicalin and OA+PA, and the model + positive drug group was given a culture medium mixture of Resmetirom 10μM and OA+PA. After mixing, the cells continued to be cultured for 24h.

[0057] Evaluation of therapeutic efficacy: (1) Oil Red O staining. The specific steps are as follows: discard the cell culture medium, wash twice with PBS, add Oil Red O fixative for 20 minutes, remove the fixative and wash twice with distilled water, rinse with 60% isopropanol for 20 seconds and dry, add the newly prepared Oil Red O staining solution, and the staining solution needs to be filtered with a 0.45μm filter membrane before use. Add 500μL of Oil Red O staining solution to each well, soak for 10 minutes, remove the staining solution and wash with PBS for 3 to 5 times until there is no excess staining solution. Soak the stained cells in PBS and observe and take pictures under a microscope. (2) Bodipy fluorescence staining. The specific steps are as follows: discard the cell culture medium, wash twice with PBS, add 4% paraformaldehyde to fix at room temperature for 15 minutes, remove the fixative and wash twice with distilled water, add the newly prepared Bodipy493 / 503 staining solution to stain for 10 minutes and then remove the staining solution, wash 3 to 5 times with PBS, add an appropriate volume of Staining Solution, incubate at room temperature in the dark for 10 minutes, wash twice with PBS, and soak the stained cells in PBS and observe and photograph them under a fluorescence microscope.

[0058] Test results: Figure 3 As shown, compared with the model group, both low and high doses of baicalin could significantly improve lipid accumulation in L02 and HepG2 hepatocytes.

[0059] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. The use of baicalin in the preparation of drugs for preventing or treating fatty hepatitis associated with metabolic dysfunction.

2. The use according to claim 1, It is characterized in that The drug is a drug capable of improving weight gain and / or weight loss caused by metabolic dysfunction-related fatty hepatitis.

3. The use according to claim 1, It is characterized in that The drug is a drug that can reduce the ALT level and / or AST level in serum.

4. The use according to claim 1, It is characterized in that The drug is a drug that can reduce the TC content and / or TG content in serum.

5. The use according to claim 1, It is characterized in that The drug is a drug capable of improving hepatic fatty degeneration.

6. The use according to claim 1, It is characterized in that The drug is a drug capable of improving ballooning degeneration of hepatocytes.

7. The use according to claim 1, It is characterized in that The drug is a drug capable of improving lipid accumulation, inflammation in liver lobule, liver fibrosis and lipid deposition in normal human liver cells or lipid deposition in human liver cancer cells.

8. The use according to any one of claims 1 to 7, It is characterized in that The dosage of baicalin is 5 to 15 mg / kg.

9. The use according to any one of claims 1 to 7, It is characterized in that The drug is in the form of tablets, capsules, granules, oral liquids, premixes, pills or sustained-release preparations for oral administration, or ointments or injections for non-oral administration, either alone or mixed with pharmaceutically acceptable excipients or diluents.

10. A drug for preventing or treating fatty hepatitis associated with metabolic dysfunction, It is characterized in that It comprises baicalin and one or more pharmaceutically acceptable carriers and / or excipients, or comprises baicalin and other drugs for treating fatty hepatitis associated with metabolic dysfunction.

Citation Information

Patent Citations

  • Application of baicalein as NQO1 inhibitor in prevention or treatment of related diseases

    CN115337298A

  • Traditional Chinese medicine composition for treating non-alcoholic steatohepatitis as well as preparation method and application thereof

    CN118021864A